Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.

2.

Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.

3.

Treating advanced prostate cancer

4.

Older Adults With Advanced Cancer Prioritize Quality of Life

5.

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot